

Renato Vellucci

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5011185/publications.pdf>

Version: 2024-02-01

32
papers

836
citations

516215

16
h-index

500791

28
g-index

33
all docs

33
docs citations

33
times ranked

1119
citing authors

#	ARTICLE	IF	CITATIONS
1	Oxycodone/Acetaminophen: The Tailoring Combination Treatment for Specific Clinical Profile of Opioid Well-Responsive Cancer Pain. <i>Cancer Management and Research</i> , 2021, Volume 13, 1747-1756.	0.9	2
2	Personalizing Cancer Pain Therapy: Insights from the Rational Use of Analgesics (RUA) Group. <i>Pain and Therapy</i> , 2021, 10, 605-617.	1.5	8
3	Pain reduction induced by tapentadol in patients with musculoskeletal chronic pain fosters better sleep quality. <i>Drugs in Context</i> , 2021, 10, 1-13.	1.0	0
4	A Call to Action by the Italian Mesotherapy Society on Scientific Research. <i>Drug Design, Development and Therapy</i> , 2021, Volume 15, 3041-3047.	2.0	6
5	Evidence based recommendations on mesotherapy: an update from the Italian society of Mesotherapy. <i>Clinica Terapeutica</i> , 2021, 171, e37-e45.	0.2	3
6	Open Issues and Practical Suggestions for Telemedicine in Chronic Pain. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 12416.	1.2	25
7	Breakthrough Cancer Pain Clinical Features and Differential Opioids Response: A Machine Learning Approach in Patients With Cancer From the IOPS-MS Study. <i>JCO Precision Oncology</i> , 2020, 4, 1339-1349.	1.5	10
8	Mesotherapy: From Historical Notes to Scientific Evidence and Future Prospects. <i>Scientific World Journal, The</i> , 2020, 2020, 1-9.	0.8	20
9	Understanding osteoporotic pain and its pharmacological treatment. <i>Osteoporosis International</i> , 2018, 29, 1477-1491.	1.3	28
10	Oral Prolonged-Release Oxycodone/Naloxone for Managing Pain and Opioid-Induced Constipation: A Review of the Evidence. <i>Pain Practice</i> , 2018, 18, 647-665.	0.9	31
11	Factors Influencing the Clinical Presentation of Breakthrough Pain in Cancer Patients. <i>Cancers</i> , 2018, 10, 175.	1.7	44
12	Understanding osteoporotic pain and its pharmacological treatment: supplementary presentation. <i>Osteoporosis International</i> , 2018, 29, 2153-2154.	1.3	6
13	Assessment and treatment of breakthrough cancer pain: from theory to clinical practice. <i>Journal of Pain Research</i> , 2017, Volume 10, 2147-2155.	0.8	21
14	High dosage of a fixed combination oxycodone/naloxone prolonged release: efficacy and tolerability in patients with chronic cancer pain. <i>Supportive Care in Cancer</i> , 2017, 25, 3051-3058.	1.0	9
15	Cost-effectiveness analysis of oral fentanyl formulations for breakthrough cancer pain treatment. <i>PLoS ONE</i> , 2017, 12, e0179523.	1.1	6
16	Bone pain mechanism in osteoporosis: a narrative review. <i>Clinical Cases in Mineral and Bone Metabolism</i> , 2016, 13, 97-100.	1.0	24
17	Reply Letter to the Editor: What to Do, and What Not to Do, When Diagnosing and Treating Breakthrough Cancer Pain (BTcP): Expert Opinion. <i>Drugs</i> , 2016, 76, 1063-1065.	4.9	3
18	What to Do, and What Not to Do, When Diagnosing and Treating Breakthrough Cancer Pain (BTcP): Expert Opinion. <i>Drugs</i> , 2016, 76, 315-330.	4.9	32

#	ARTICLE	IF	CITATIONS
19	Implications of analgesics use in osteoporotic-related pain treatment: focus on opioids. <i>Clinical Cases in Mineral and Bone Metabolism</i> , 2016, 13, 89-92.	1.0	6
20	Pharmacoeconomic Considerations About Breakthrough Cancer Pain. <i>Value in Health</i> , 2015, 18, A665-A666.	0.1	4
21	Long-term efficacy and tolerability of intranasal fentanyl in the treatment of breakthrough cancer pain. <i>Supportive Care in Cancer</i> , 2015, 23, 1349-1354.	1.0	22
22	Patients' and physicians' perspectives on opioid therapy for chronic cancer and musculoskeletal pain in Germany, Italy, and Turkey: PAIN RESEARCH (PARES) survey. <i>Current Medical Research and Opinion</i> , 2014, 30, 339-347.	0.9	6
23	Pathogenesis and clinical aspects of pain in patients with osteoporosis. <i>Clinical Cases in Mineral and Bone Metabolism</i> , 2014, 11, 169-72.	1.0	20
24	Use of opioids for treatment of osteoporotic pain. <i>Clinical Cases in Mineral and Bone Metabolism</i> , 2014, 11, 173-6.	1.0	13
25	Heterogeneity of Chronic Pain. <i>Clinical Drug Investigation</i> , 2012, 32, 3-10.	1.1	67
26	Barriers to Pain Management. <i>Clinical Drug Investigation</i> , 2012, 32, 11-19.	1.1	53
27	The Appropriate Treatment of Chronic Pain. <i>Clinical Drug Investigation</i> , 2012, 32, 21-33.	1.1	70
28	Adverse Effects Associated with Non-opioid and Opioid Treatment in Patients with Chronic Pain. <i>Clinical Drug Investigation</i> , 2012, 32, 53-63.	1.1	149
29	Breakthrough Pain in Patients Referred to Pain Clinics: The Italian Pain Network Retrospective Study. <i>Advances in Therapy</i> , 2012, 29, 464-472.	1.3	19
30	Effects of Opioid Rotation in Chronic Pain Patients. <i>Clinical Drug Investigation</i> , 2010, 30, 39-47.	1.1	14
31	Endocrine consequences of opioid therapy. <i>Psychoneuroendocrinology</i> , 2009, 34, S162-S168.	1.3	86
32	Pain Biomarkers. <i>Clinical Drug Investigation</i> , 2009, 29, 41-46.	1.1	29